NasdaqCM - Nasdaq Real Time Price USD

Curis, Inc. (CRIS)

2.4800

+0.3700

+(17.54%)

At close: May 1 at 4:00:01 PM EDT

Earnings Preview: Insmed (INSM) Q1 Earnings Expected to Decline

Insmed (INSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 18 hours ago

INSM

CRIS
+17.54%
Curis to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on May 6, 2025

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its first quarter 2025 financial and operating results on Tuesday, May 6, 2025, at 8:00 a.m. ET. Management will host a conference call and simultaneous webcast on the same day at 8:30 a.m. ET.

PR Newswire 2 days ago

CRIS
+17.54%
Analyst Forecasts For Curis, Inc. (NASDAQ:CRIS) Are Surging Higher

Curis, Inc. ( NASDAQ:CRIS ) shareholders will have a reason to smile today, with the analysts making substantial...

Simply Wall St. 28 days ago

CRIS
+17.54%
Curis to Present at Upcoming Healthcare Conference in April

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that James Dentzer, President and Chief Executive Officer of Curis, will participate in the Jones Healthcare and Technology Innovation Conference on Wednesday, April 9, 2025 with a fireside chat and company presentation.

PR Newswire 29 days ago

CRIS
+17.54%
Curis, Inc. (NASDAQ:CRIS) Just Reported Full-Year Earnings And Analysts Are Lifting Their Estimates

It's been a mediocre week for Curis, Inc. ( NASDAQ:CRIS ) shareholders, with the stock dropping 19% to US$2.10 in the...

Simply Wall St. 30 days ago

CRIS
+17.54%
Curis Inc (CRIS) Q4 2024 Earnings Call Highlights: Financial Improvements and Promising ...

Curis Inc (CRIS) reports reduced net loss and expenses, while advancing its emavusertib program with potential accelerated approvals.

GuruFocus.com last month

CRIS
+17.54%
Q4 2024 Curis Inc Earnings Call

Q4 2024 Curis Inc Earnings Call

Thomson Reuters StreetEvents last month

CRIS
+17.54%
Curis: Q4 Earnings Snapshot

LEXINGTON, Mass. AP) — Curis Inc. CRIS) on Monday reported a loss of $9.6 million in its fourth quarter.

Associated Press Finance last month

CRIS
+17.54%
Curis Provides Fourth Quarter 2024 Business Update

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today reported its business update and financial results for the quarter ended December 31, 2024.

PR Newswire last month

CRIS
+17.54%
Curis Full Year 2024 Earnings: Revenues Beat Expectations, EPS In Line

Curis ( NASDAQ:CRIS ) Full Year 2024 Results Key Financial Results Revenue: US$10.9m (up 8.8% from FY 2023). Net loss...

Simply Wall St. last month

CRIS
+17.54%
Curis to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on March 31, 2025

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its fourth quarter 2024 financial and operating results on Monday, March 31, 2025, at 8:00 a.m. ET. Management will host a conference call and simultaneous webcast on the same day at 8:30 a.m. ET.

PR Newswire last month

CRIS
+17.54%
Curis Announces Additional Data from TakeAim Leukemia Study

Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, yesterday presented data from the TakeAim Leukemia study (CA-4948-102) in relapsed/refractory (R/R) Acute Myeloid Leukemia (AML) at the 66th ASH annual meeting.

PR Newswire 4 months ago

CRIS
+17.54%
Curis Third Quarter 2024 Earnings: Beats Expectations

Curis ( NASDAQ:CRIS ) Third Quarter 2024 Results Key Financial Results Revenue: US$2.93m (up 3.5% from 3Q 2023). Net...

Simply Wall St. 5 months ago

CRIS
+17.54%
Q3 2024 Curis Inc Earnings Call

Q3 2024 Curis Inc Earnings Call

Thomson Reuters StreetEvents 5 months ago

CRIS
+17.54%
Curis Inc (CRIS) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges and ...

Curis Inc (CRIS) reports reduced net loss and promising clinical trial results, while addressing financial and regulatory hurdles.

GuruFocus.com 5 months ago

CRIS
+17.54%
Curis (CRIS) Reports Q3 Loss, Tops Revenue Estimates

Curis (CRIS) delivered earnings and revenue surprises of 9.57% and 3.20%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 5 months ago

CRIS
+17.54%
Curis: Q3 Earnings Snapshot

LEXINGTON, Mass. AP) — Curis Inc. CRIS) on Thursday reported a loss of $10.1 million in its third quarter.

Associated Press Finance 5 months ago

CRIS
+17.54%
Curis Provides Third Quarter 2024 Business Update

Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today reported its business update and financial results for the quarter ended September 30, 2024.

PR Newswire 5 months ago

CRIS
+17.54%
Curis to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on November 14, 2024

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its third quarter 2024 financial and operating results on Thursday, November 14, 2024, at 8:00 a.m. ET. Management will host a conference call and simultaneous webcast on the same day at 8:30 a.m. ET.

PR Newswire 5 months ago

CRIS
+17.54%
Curis price target lowered to $20 from $26 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Curis (CRIS) to $20 from $26 and keeps a Buy rating on the shares. The firm cites dilution from this week’s registered direct offering for the target cut. Additional data from the TakeAim lymphoma study is expected in December and in Q1 of 2025, the analyst tells investors in a research note. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts

TipRanks 5 months ago

CRIS
+17.54%

Performance Overview

Return	CRIS	S&P 500 (^GSPC)
YTD	-18.95%	-4.72%
1-Year	-84.49%	+11.67%
3-Year	+172.53%	+35.63%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Curis, Inc. (CRIS)

Earnings Preview: Insmed (INSM) Q1 Earnings Expected to Decline

Curis to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on May 6, 2025

Analyst Forecasts For Curis, Inc. (NASDAQ:CRIS) Are Surging Higher

Curis to Present at Upcoming Healthcare Conference in April

Curis, Inc. (NASDAQ:CRIS) Just Reported Full-Year Earnings And Analysts Are Lifting Their Estimates

Curis Inc (CRIS) Q4 2024 Earnings Call Highlights: Financial Improvements and Promising ...

Q4 2024 Curis Inc Earnings Call

Curis: Q4 Earnings Snapshot

Curis Provides Fourth Quarter 2024 Business Update

Curis Full Year 2024 Earnings: Revenues Beat Expectations, EPS In Line

Curis to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on March 31, 2025

Curis Announces Additional Data from TakeAim Leukemia Study

Curis Third Quarter 2024 Earnings: Beats Expectations

Q3 2024 Curis Inc Earnings Call

Curis Inc (CRIS) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges and ...

Curis (CRIS) Reports Q3 Loss, Tops Revenue Estimates

Curis: Q3 Earnings Snapshot

Curis Provides Third Quarter 2024 Business Update

Curis to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on November 14, 2024

Curis price target lowered to $20 from $26 at H.C. Wainwright

Performance Overview